CClinicalTrials.gg
Status unknownNCT03302689Updated Oct 25, 2017

Comparison Levobupivacaine and Ropivacaine for TAP-block After Caesarean Section

An interventional study of Levobupivacaine Solution and Ropivacaine Solution in Pain, Postoperative, sponsored by Alexandr Ronenson. Status unknown at 1 site in Russian Federation. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-25.

Sponsored by Alexandr Ronenson · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Sex
Female
01

Study summary

Randomized, double-blind, controlled trial: a comparison of Levobupivacaine and Ropivacaine for postoperative analgesia using TAP-block

Objectives:

  1. VAS score during the first 12 hours
  2. Determine which drug is more effective for postoperative analgesia in the first 12 hours after surgery
  3. Side effects
Read the detailed description

For TAP-block was used Hirokain® (Levobupivacaine) . Injectable solution 7.5 mg / ml; ampoule polypropylene 10 ml, a pack of cardboard 10; No. ЛП-003106, 2015-07-21 to 2020-07-21 from EbbVi Ltd. (Russia); manufacturer: Kurida AS (Norway); Packer: AbbVi S.r.l. (Italy), or Ropivacaine Kabi (Ropivacaine Kabi) (Ropivacaine) Solution for injection 7.5 mg / ml; ampoule polypropylene 1 10 ml, a pack of cardboard 5; EAN code: 4607085481524; No. ЛП-002897, 2015-03-04 to 2020-03-04 from Fresenius Kabi Deutschland GmbH (Germany); manufacturer: Fresenius Kabi Norge (Norway).

Both preparations were diluted to a volume of 50 ml, at a concentration of 3 mg / ml.

It was performed by TAP-block in-plain with a 22G needle Quincke, on both sides, and 25 ml on each side was injected.

The pain syndrome was assessed with admission, and every 2 hours during the first 12 hours after the operation, using a digital scale on the VAS.

All patients received NSAIDs (Ketorol 3 mg IV every 6 hours from admission)

Additionally:

Paracetamol IV infusion 100 ml with VAS = 4 score, lockout time 6 hours Tramadol 5% - 2 ml IM with VAS = or > 5 score, lockout time 6 hours

02

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • TAP-block
  • VAS of pain
  • Cesarean section
  • Postoperative analgesia
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Cesarean section pfannenstiel incision under spinal anesthesia
  • Spinal anesthesia with Bupivacaine heavy 0,5%
  • Without any adjuvants

Exclusion criteria

Exclusion Criteria:

  • Any other anesthesia exept spinal
  • Any other surgical incision
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Ropivacaine

    TAP-block with Ropivacaine Solution

    Drug: Ropivacaine Solution

  • Experimental
    Levobupivacaine

    TAP-block with Levobupivacaine Solution

    Drug: Levobupivacaine Solution

Interventions

  • DrugLevobupivacaine Solution

    TAP-block with Levobupivacaine 0,3% - 25 ml from each side

    Also known as: Levo

  • DrugRopivacaine Solution

    TAP-block with Ropivacaine 0,3% - 25 ml from each side

    Also known as: Rop

05

What researchers measure

Primary outcomes

  1. Level of pain

    Measurement of pain on a VAS scale (from 0 to 10 points)

    Time frame: 12 hours

Secondary outcomes

  1. The need for additional analgesics (Paracetamol, Tramadol)

    Paracetamol IV infusion 100 ml with VAS = 4 score, Tramadol 5% - 2 ml IM with VAS = 5 scores

    Time frame: 12 hours

06

Study locations

1 site
  • Tver Regional Perinatal Center
    Tver, Russian Federation
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03302689
Lead sponsor
Alexandr Ronenson
Responsible party
Alexandr Ronenson (Head of department of Anaesthesiology and Intensive Care Unit, Tver Regional Perinatal Center) — Sponsor-investigator
First posted
Oct 5, 2017
Start date
Sep 25, 2017
Primary completion
Oct 23, 2017
Completion
Jan 1, 2018 (estimated)
Last update
Oct 25, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion